Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration.

Walsh DM, Selkoe DJ.

Protein Pept Lett. 2004 Jun;11(3):213-28. Review.

PMID:
15182223
2.

Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.

Hashimoto M, Rockenstein E, Crews L, Masliah E.

Neuromolecular Med. 2003;4(1-2):21-36. Review.

PMID:
14528050
3.

Neurodegenerative disease: amyloid pores from pathogenic mutations.

Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT Jr.

Nature. 2002 Jul 18;418(6895):291.

PMID:
12124613
4.
5.
6.

Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.

Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H.

Neuropharmacology. 2003 Jul;45(1):14-44. Review.

PMID:
12814657
7.

Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.

Meredith SC.

Ann N Y Acad Sci. 2005 Dec;1066:181-221. Review.

PMID:
16533927
8.

The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.

Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ.

Neuron. 2003 Feb 20;37(4):583-95.

9.

Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection.

Gozes I.

J Mol Neurosci. 2004;24(3):333-6. No abstract available.

PMID:
15655257
10.

Linker histone H1 binds to disease associated amyloid-like fibrils.

Duce JA, Smith DP, Blake RE, Crouch PJ, Li QX, Masters CL, Trounce IA.

J Mol Biol. 2006 Aug 18;361(3):493-505. Epub 2006 Jul 3.

PMID:
16854430
11.

Protein misfolding in neurodegenerative diseases.

Agorogiannis EI, Agorogiannis GI, Papadimitriou A, Hadjigeorgiou GM.

Neuropathol Appl Neurobiol. 2004 Jun;30(3):215-24. Review.

PMID:
15175075
12.

Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses.

Cerpa W, Dinamarca MC, Inestrosa NC.

Curr Alzheimer Res. 2008 Jun;5(3):233-43. Review.

PMID:
18537540
13.

Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.

Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM.

Cell Death Differ. 1998 Oct;5(10):832-7. Review.

14.

Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases.

Ferreira ST, Vieira MN, De Felice FG.

IUBMB Life. 2007 Apr-May;59(4-5):332-45. Review.

15.

A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.

Gallardo G, Schlüter OM, Südhof TC.

Nat Neurosci. 2008 Mar;11(3):301-8. doi: 10.1038/nn2058. Epub 2008 Feb 24.

PMID:
18297066
16.

Protein degradation in Alzheimer's disease and aging of the brain.

Tsuji T, Shimohama S.

Prog Mol Subcell Biol. 2002;29:43-60. Review. No abstract available.

PMID:
11908072
17.

A beta oligomers - a decade of discovery.

Walsh DM, Selkoe DJ.

J Neurochem. 2007 Jun;101(5):1172-84. Epub 2007 Feb 5. Review.

18.

In vitro preparation of prefibrillar intermediates of amyloid-beta and alpha-synuclein.

Lashuel HA, Grillo-Bosch D.

Methods Mol Biol. 2005;299:19-33.

PMID:
15980593
19.

Alzheimer's and Parkinson's disease--overlapping or synergistic pathologies?

Kurosinski P, Guggisberg M, Götz J.

Trends Mol Med. 2002 Jan;8(1):3-5.

PMID:
11796255
20.

Amyloid-beta aggregation.

Finder VH, Glockshuber R.

Neurodegener Dis. 2007;4(1):13-27. Review.

PMID:
17429215

Supplemental Content

Support Center